Treatment of Peritoneal Carcinomatosis Using Carboplatin-loaded Hydroxyapatite Particles

The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied. Materials and Methods: Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: gro...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-11, Vol.26 (6B), p.4603-4606
Main Authors: TAKEYAMA, Hiromitsu, MOHRI, Noriaki, MIZUNO, Isamu, AKAMO, Yoshimi, SAWAI, Hirozumi, MANABE, Tadao, YOTSUYANAGI, Toshihisa, NAKAMURA, Satoshi
Format: Article
Language:English
Subjects:
Abdomen
Animals
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - therapeutic use
Area Under Curve
Biological and medical sciences
Carboplatin - pharmacokinetics
Carboplatin - therapeutic use
Gastroenterology. Liver. Pancreas. Abdomen
Male
Medical sciences
Peritoneal Neoplasms - drug therapy
Rats
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied. Materials and Methods: Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p. Results: The survival rate of group IV was better than that of the other groups (p
ISSN:0250-7005
1791-7530